Please login to the form below

bevacizumab

This page shows the latest bevacizumab news and features for those working in and with pharma, biotech and healthcare.

treatments Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).

Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’

Global revenues for its biosimilar also reach $424m, up 80% operationally, driven mostly by recent oncology launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab) in the US and other global
Roche cites COVID-19 and biosimilars in Q2 decline

Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).
Tecentriq misses the mark in advanced ovarian cancer

The phase 3 IMagyn050 study evaluated the addition of Tecentriq (atezolizumab) to Roche’s older treatment Avastin (bevacizumab) alongside chemotherapy (paclitaxel and carboplatin) in women with advanced-stage ovarian cancer.
AZ’s comeback drug cediranib stumbles in phase 3 trial

Cediranib has been developed as a potential oral alternative to drugs like Roche’s big-selling injectable VEGF inhibitor Avastin (bevacizumab), which is already used to treat ovarian cancer and other
FDA accepts review to broaden GSK’s Zejula label

Lynparza, like Zejula, has data which backs up its use in ‘all-comer’ ovarian cancer patients – when added to Avastin (bevacizumab), the standard of care for ovarian cancer, the treatment improved

More from news
Approximately 21 fully matching, plus 186 partially matching documents found.

Cancer immunotherapy: What's on the horizon?

Roche has already chalked up the first successes pairing Tecentriq (atezolizumab) with its veteran anticancer antibody Avastin (bevacizumab) in first-line NSCLC and kidney cancer, with additional trials of the duo
Stories that can save lives

Roche instituted similar principles in the promotion of its cancer drug, Avastin (bevacizumab), which works by finding and blocking the blood supply feeding malignant tumors.
Pharma deals in July 2015

Still in Japan, a week later AZ agreed a joint venture with Fujifilm Kyowa Kirin Biologics for the development and commercialisation of a biosimilar version of bevacizumab (Avastin) in phase I
Current development and marketing of biosimilar monoclonal antibodies in Latin America

NA. Bevacizumab. Biocad. Russia. BCD-021. Clinical. NSCLC: Ph III started in Oct 2012.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

October 2020: diversity and inclusion in clinical trials round-up

According to their study, Black patients were significantly less likely than white patients to show short-term visual improvement after being given bevacizumab (Avastin), a common treatment used in the
The Biosimilar Challenge

These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. .

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Medical Writers (All levels) Editorial / Scientific Leads & ...: Highly Competitive Remuneration packages

Editorial Traffic Manager, Medical Communications Agency, London...: up to £45K

Head of Strategic Planning, Healthcare Advertising/ Brand comms,...: Six figure salary

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Account Manager - Creative Healthcare Communications - South Wes...: Excellent Remuneration

Group Account Director, Healthcare Advertising/ Brand comms, Lon...: 8 month contract up to £90K

Add my company

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

How innovating study sites can improve patient recruitment efficiency: There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown: Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it: If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....

Email:
Password: